Objective. A crucial feature of OA is cartilage degradation. This process is mediated by pro-inflammatory cytokines, among other factors, via induction of matrix-degrading enzymes. Interleukin 37 (IL37) is an antiinflammatory cytokine and is efficient in blocking the production of pro-inflammatory cytokines during innate immune responses. We hypothesize that IL37 is therapeutic in treating the inflammatory cytokine cascade in human OA chondrocytes and can act as a counter-regulatory cytokine to reduce cartilage degradation in OA.
(ADAMTSs), and the inhibition of synthesis of extracellular matrix molecules. For the maintenance of cartilage integrity, it is necessary to have a proper balance between these anabolic and catabolic processes. In OA, the catabolic processes are dramatically accelerated while the anabolic processes are suppressed; for example, upregulation of the above-mentioned cartilage matrix-degrading enzymes drives the degradation of the cartilage matrix in OA, resulting in cartilage destruction [14] .
Pro-inflammatory cytokines are involved in skewing the above-mentioned balance towards catabolic processes [58] . Elevated concentrations of IL1b are found in OAaffected joints, resulting in the production and release of MMPs and ADAMTSs [912] . This leads to increased cleavage of aggrecan and collagen type II molecules, and it therefore promotes cartilage destruction [13] . Additionally, IL1b induces the release by chondrocytes of other pro-inflammatory cytokines, such as IL6 and IL8 [1417] . In articular chondrocytes, IL6 downregulates, in the presence of the IL6 soluble receptor, the transcription of aggrecan and collagen type II and enhances IL1b-induced proteoglycan degradation [1821] . Also in vivo, elevated mRNA and protein levels of MMPs are observed when IL6 is intra-articularly injected in mouse knee joints [22] . IL8 promotes cartilage destruction by increasing the production of MMP1 and inducing proteoglycan loss and chondrocyte apoptosis [6] . Additionally, in bovine chondrocytes, IL8 induces hypertrophic differentiation of chondrocytes as characterized by increased collagen type X and MMP13 expression [23] . These processes result in impaired cartilage homeostasis and calcification of the cartilage, thereby promoting cartilage degradation. In view of these negative effects, regulating the production of these catabolic cytokines and enzymes is a promising treatment option for OA.
Recently, IL37 has been identified as new member of the IL1 gene family and a potent inhibitor of innate immune responses [24] . In the human THP-1 monocyte cell line and the human A549 epithelial cell line, the cytokine IL37 potently reduced IL1b-induced expression of IL1a, IL8 and TNFa [24] . Besides these in vitro culture experiments, the anti-inflammatory effects of IL37 have also been shown in vivo. For instance, IL37 transgenic mice are protected against lipopolysaccharide (LPS)-induced endotoxic shock [24] , and intraperitoneal injection of recombinant human IL37 reduces lung inflammation and lung damage in mice with pulmonary aspergillosis [25] . Also in inflammatory rheumatic diseases, a protective effect of IL37 has been demonstrated. RA patients show elevated plasma concentrations of IL37, which is correlated with the disease activity (DAS 28) [26] . In addition, IL37 suppressed the production of IL1b, IL6 and IL17 in both peripheral blood mononuclear cells (PBMCs) from RA patients and mouse models of arthritis [27] . The presence of catabolic factors during OA and the observed potent counter-regulatory feedback loop between catabolic stimuli and IL37 in inflammatory disease models lead to the hypothesis that IL37 can be used as an interesting target for a treatment option for OA.
In this study, we investigated the interplay between catabolic stimuli and IL37 in human OA cartilage and whether IL37 has an anti-catabolic effect in human chondrocytes. To accomplish this, we assessed the induction of IL37 by catabolic stimuli, and we used an adenoviral overexpression model as a therapeutic approach to examine the anticatabolic capacity of IL37 in human OA chondrocytes.
Methods
Tissue acquisition and chondrocyte cell culture Cartilage was obtained from eight anonymized OA patients undergoing total knee or hip arthroplasty. The OA material is considered as surgery surplus material. Patients of the Radboud University Medical Center Nijmegen, The Netherlands are informed about the potential anonymized use of this material and are able to decline the use of their material for research. According to the Dutch law, informed consent is therefore not necessary. In addition, the material we received was anonymized, meaning that neither the patients or nor anyone else could identify the patients with certainty. Therefore, we did not need the approval of an ethics committee.
To obtain chondrocytes, cartilage slices were digested overnight with collagenase B (Roche Diagnostics, Mannheim, Germany) 2 mg/ml in DMEM/F12 1:1. For gene expression studies, chondrocytes were seeded at 1 Â 10 5 cells/cm 2 in a 24-well culture plate (Cellstar; Greiner Bio-one, Alphen aan de Rijn, the Netherlands), and for protein expression studies, chondrocytes were seeded at 1 Â 10 5 cells/cm 2 in a six-well culture plate (Cell star; Greiner Bio-one, Alphen aan de Rijn, the Netherlands). After seeding of the cells in the culture plates, the chondrocytes were cultured for 1 week in DMEM/Ham's F12 (1:1), supplemented with 10% fetal calf serum, 100 mg/l sodium pyruvate, 100 U/ml penicillin and 100 mg/ml streptomycin in standard conditions [5% CO 2 (v/v), 37 C, 95% humidity]. The chondrocytes were serum starved for 24 h prior to the 24 h stimulation with the pro-inflammatory factors IL1b (10 ng/ml; R&D, Minneapolis, US), TNFa (30 ng/ml; R&D, Minneapolis, US) or 10% human OA synovium-conditioned medium (OAS-CM). The OAS-CM was produced as described previously [28] .
Immunohistochemical detection of IL37 in paraffin sections
Human OA cartilage was fixed in 4% phosphate-buffered formalin (pH 7.0) for 7 days, dehydrated with an automated tissue-processing apparatus (Sakura Tissue Tek VIP, USA) and embedded in paraffin. Tissue sections 7 mM thick were prepared and stained with Safranin O and Fast Green (Brunschwig Chemie, The Netherlands). For IL37 immunohistochemistry, cartilage sections were incubated with human anti-rabbit IL37 antibody (ab116282, 5 mg/ml; UK) and visualized with an horseradish perioxidase biotinylated rabbit-anti goat antibody. Mayer's haematoxylin (Merck, Germany) was used for counterstaining. Normal goat IgG (R&D, Minneapolis, US) was used as the negative control.
Construction of the IL37 adenovirus
An adenovirus overexpressing IL37 (Ad-IL37) was generated from pTarget-IL37, kindly provided by Professor C. Dinarello, University of Colorado in Denver [29] . The IL37 sequence was cloned from the cDNA from a human spleen library (CLONTECH HL0011B; BD Biosciences CLONTECH) and inserted into a pTarget expression plasmid (Promega) by using the restrictions sites Xho1 and Not1. Subsequently, the IL37 sequence was cut out of this pTarget vector by using EcoRI. With the use of a blunt ligation step, the IL37 sequence was cloned into a PCR-script vector (Strategene) treated with EcoRV. To produce an adenovirus, it was necessary to transfer the IL37 sequence to the pShuttle vector (Stratagene). IL37 was cloned from the PCR-Script vector into the pShuttle vector by using the restriction sites SalI and NotI (supplementary Fig. 1 , available at Rheumatology Online). Hereafter, the adenovirus sequence was verified by Sanger sequencing, using the forward primer CTGGTTT AGTGAACCGTCAG and reverse primer GTTATCTAGATC CGGTGGA. The adenovirus was produced with the AdEasy Adenoviral Vector System (Stratagene) by transfection of N52E6 cells with this pShuttle-IL37 vector. Briefly, the pShuttle-IL37 vector was linearized by digesting with the restriction endonuclease PmeI and subsequently electroporated with the Backbone plasmid pAdEasy-1. Recombinants are selected for kanamycin resistance, digested with PacI to liberate both inverted terminal repeats and transfected into N52E6 cells for virus production.
Viral transduction
Chondrocytes were transduced by Ad-IL37 for 3 h at 37 C on a rollerbench, in a multiplicity of infection of 200 in a suspension of 1 Â 10 6 cells/ml in serum-free DMEM/F12
(1:1). An adenovirus overexpressing luciferase was used as the control (Ad-Luc). Subsequently, cells were washed with saline, plated at 2 Â 10 5 cells/cm 2 , and cultured for 1 week in standard conditions. Thereafter, cells were stimulated with 10 ng/ml IL1b (R&D) for 24 h.
mRNA isolation and quantitative real-time PCR mRNA was isolated from chondrocytes using 500 ml of TRI-reagent (Sigma-Aldrich) as described in the manufacturer's protocol. The mRNA concentration was determined using a NanoDrop photospectrometer, and 1 mg of mRNA was treated with 1 ml DNAse (Life Technologies, USA) for 15 min at room temperature and incubated with 1 ml 25 mM EDTA (Life Technologies, USA) for 10 min at 65 C. The mRNA was reverse transcribed to complementary DNA using 1.9 ml ultrapure water, 2.4 ml 10Â DNAse buffer, 2.0 ml 0.1 M dithiothreitol, 0.8 ml 25 mM dNTP, 0.4 mg oligo dT primer, 1 ml 200 U/ml M-MLV reverse transcriptase (Life Technologies, USA) and 0.5 ml 40 U/ml RNAsin (Promega, The Netherlands) in a single-step reverse transcription: 5 min at 25 C, 60 min at 39 C and 5 min at 95 C. Quantitative PCR was performed using SYBR green master mix (Applied Biosystems) with 0.25 mM primers (Biolegio; Table 1), with the following amplification protocol: 10 min at 95 C, followed by 40 cycles of 15 s at 95 C and 1 min at 60 C. Melting curves were constructed to determine the specificity of the product. To calculate the relative gene expression, the average of the reference genes glyceraldehyde-3-phosphate dehydrogenase and ribosomal protein S27A (RPS27A) was used.
Protein isolation and western blot Cells were lysed using lysis buffer (Cell Signaling) containing a protease inhibitor cocktail (Roche Diagnostic). Cell lysates were sonicated and protein concentration was equalized after performing a bicinchoninic acid assay (Thermo Scientific, USA). The supernatant was concentrated with Amicon Ultra centrifugal filters 10K (Merk Millipore) to a volume of 50 ml. Proteins were precipitated (using 30% trichloroacetic acid, 0.1% dithiothreitol in acetone, À20 C), washed (0.2% dithiothreitol w/v in acetone, À20 C) and dissolved in SDS sample solubilization buffer (1% SDS and 100 mM Tris, pH 9.5). Samples were boiled for 10 min in Laemmli sample buffer. Proteins were separated on a 10% reducing bisacrylamide SDSPAGE gel, and transferred onto a 0.1 mm pore nitrocellulose membrane using wet transfer (Towbin buffer, 2 h, 275 mA at 4 C). Non-specific protein binding was blocked for 1 h with 5% non-fat dry milk (Campina, The Netherlands) in TBS-T (15 mM TrisHCl, pH 7.4, 0.1% Tween). Membranes were incubated overnight at 4 C with primary antibodies against IL37 (AF1975, 1:1500) or IL1b (AF-201-NA, 1:1500; R&D, USA) and then incubated with polyclonal rabbit anti-goat labelled with horseradish perioxidase (1:1500; DAKO, Belgium) for 2 h. Enhanced chemiluminescence using ECL prime kit (GE Healthcare, UK) was used to visualize proteins with the ImageQuant LAS4000 (Leica, Germany). b-Actin rabbit mAb (1:1500, 13E5; Cell Signaling) or Ponceau S [0.1% w/v, in 5% acetic acid (Sigma)] staining was used as the loading control.
Protein measurement using Luminex technology
To determine IL6, IL8, MMP1, MMP3 and MMP13 levels in chondrocyte culture supernatants, Luminex multianalyte technology in combination with multiplex MMP/cytokine kits (Milliplex, Millipore) were used. Protein levels were measured in 50 ml of culture medium, diluted 1:25 in assay buffer. The sensitivity of the Luminex system was <5 pg/ml.
Statistical analysis
Differences between experimental groups were tested for statistical significance using Graphpad Prism 5.03 (Graphpad Software, Inc., San Diego, CA, USA) via a one-way analysis of variance followed by the Tukey's multiple comparison test to study differences between all groups as well as a one-tailed Student's paired t-test to evaluate the impact of IL37 transduction within the IL1b-stimulated groups. Differences were considered as significant at P < 0.05.
Results
IL1b is a potent inducer of IL37 expression in human OA chondrocytes IL37 expression in human OA cartilage was investigated by an immunohistochemically staining for IL37 (n = 3) in OA cartilage slices. A clear staining of the chondrocytes was observed (Fig. 1A) . To study the interplay between inflammation and IL37 expression, chondrocytes from eight OA donors were stimulated for 24 h with IL1b (10 ng/ml), human OAS-CM (10%) or TNFa (30 ng/ml). IL1b significantly (P 4 0.001) induced IL37 gene expression 6.8-fold (2.76 ÁC t ), whereas TNFa (1.44 ÁC t ; 2.7-fold) or OAS-CM (0.97 ÁC t ; 1.9-fold) did not (Fig. 1B) . At the protein level, IL1b as well as OAS-CM and TNFa stimulation strongly induced IL37 protein expression (Fig. 1C) . As IL1b was the only significant inducer of IL37, we continued our studies with IL1b stimulation. Western blot analysis detected four bands for IL37 protein expression; this is possibly the result of alternatively splicing of IL37 [31] . To include a positive control, we took a long a THP-1 cell lysate stimulated with LPS (10 mg/ml), which shows the same pattern of bands as the primary human OA chondrocytes (supplementary Fig. 2 , available at Rheumatology Online).
Functional characterization of the adenoviral IL37 construct
To study the anti-catabolic effect of IL37, we generated an adenoviral overexpression model for human IL37 (Ad-IL37). First, we characterized the adenovirus by transducing chondrocytes with Ad-IL37 or the luciferase control virus (Ad-Luc). Ad-IL37 shows significant amplification of IL37 mRNA expression (20 ÁC t ), which was further enhanced by IL1b (10 ng/ml; 2.3 ÁC t ; Fig. 2A ). To investigate whether mRNA was translated into protein, western blot analysis was performed. Ad-IL37 strongly induced IL37 protein expression, both intracellulary, as measured in the cell lysates (Fig. 2B) and extracellulary, as measured in the supernatant (Fig. 2C) ; this expression was further induced by IL1b. Furthermore, the western blot showed only one band at the size of 24 kDa, indicating that only the longest biologically functional splice variant, IL37b, was made [31] . These data confirm the functionality of our IL37 adenovirus.
Overexpression of IL37 reduces the IL1b-induced production of pro-inflammatory cytokines in human OA chondrocytes
To examine whether elevated IL37 levels resulted in a reduced IL1b-driven cytokine production, human chondrocytes were transduced with Ad-IL37 or Ad-Luc followed by IL1b stimulation. Ad-IL37 did not affect basal cytokine gene expression, but significant reductions were observed in the IL1b-driven expression of IL1, IL6 and IL8 by Ad-IL37 of 42, 28 and 48%, respectively, compared with the combined Ad-Luc and IL1b stimulation (Fig. 3A) . For protein analysis, it was not possible to detect IL1b expression by the Luminex assay; therefore, we analysed IL1b by western blot analysis and analysed the cytokines IL6 and IL8 with Luminex. Ad-IL37 strongly reduced intracellular IL1b-induced IL1b expression (Fig. 3B) . Furthermore, Ad-IL37 significantly reduced IL1b-induced IL8 secretion by 44% and showed a trend towards a decrease of IL6 secretion (Fig. 3C ). These data revealed that elevated levels of IL37 could dampen the IL1b-driven inflammatory status of human OA chondrocytes.
Overexpression of IL37 decreases the IL1b-induced production of catabolic enzymes in human OA chondrocytes As pro-inflammatory cytokines are potent inducers of cartilage matrix-degrading enzymes, such as MMPs and ADAMTSs, we explored whether elevated levels of IL37 could influence the expression of these catabolic enzymes. Therefore, chondrocytes were transduced with Ad-IL37 or Ad-Luc and subsequently stimulated with IL1b. Ad-IL37 did not alter basal MMP1, MMP3 and MMP13 gene expression (Fig. 4A) , but significant reductions were observed in the IL1b-induced gene expression of MMP1, MMP3 and MMP13 by Ad-IL37 by 35, 32 and 29%, respectively, compared with the combined Ad-Luc and IL1b conditions. Furthermore, Ad-IL37 significantly 
GTTAAGCTGGCTGTCCTGAAA CATCAGAAGGGCACTCTCG reduced IL1b-induced MMP3 and MMP13 protein expression by 26 and 21%, respectively, in the supernatant, and induced a trend towards lower MMP1 expression (Fig. 4B) . In addition to MMPs, Ad-IL37 significantly reduced ADAMTS5 gene expression in both basal conditions and in presence of IL1b. However, there was no IL1b-driven induction of ADAMTS5 expression (Fig. 4C) . The expression of ADAMTS4 in the chondrocytes was very low; therefore, it was not possible to observe a further downregulation in ADAMTS4 expression levels on addition of Ad-IL37 (Fig. 4C) . Taken together, our results show that elevated levels of IL37 can counter-regulate the IL1b-driven production of cartilage matrix-degrading enzymes.
Discussion
The present study establishes IL37 as a potential therapeutic peptide that can control catabolic processes in OA chondrocytes. Prohibiting impaired cartilage homeostasis and cartilage degradation could result in the maintenance of the cartilage. IL37 is a member of the IL1 family and shares the same structural pattern of 12 b-barrel strands as other IL1 family members [23] . However, in contrast to other IL1 family members, IL37 is unique in the way that it functions as an intracellular anti-inflammatory cytokine. IL37 expression is found in different tissues, such as the testis, thymus and uterus, and can be induced in peripheral blood mononuclear cells and epithelial cells under influence of an inflammatory stimulus [24, 32, 33] . In rheumatoid arthritis, the amount of IL37 in the synovial lining and plasma are higher in active RA compared with healthy controls [24, 26, 34] . In addition, IL37 plasma concentrations are positively correlated with the disease activity score, indicating that also in rheumatic diseases, pro-inflammatory cytokines are able to upregulate IL37 expression [26] . In the present study we show, for the first time, that IL37 is expressed in human OA cartilage. Moreover, in primary OA chondrocytes, we observed that IL1b was capable of inducing IL37 gene and protein expression after 24 h stimulation. The increase in IL37 expression induced by pro-inflammatory cytokines can occur via two different mechanisms: the first is via enhanced transcription of IL37; the second is via stabilization of IL37 mRNA. IL37 mRNA contains a critical instability region located within the coding region of exon 5, as identified by a study showing that removal of this exon 5 results in significantly higher IL37 expression [35] . Additionally, it has been shown that pro-inflammatory factors, such as LPS, can increase IL37 mRNA and protein levels, indicating that inflammatory stimuli are able to give stability to the IL37 transcript [31] .
Apart from IL1b, TNFa has also been shown to induce IL37 protein expression in human PBMCs and both IL37 protein and IL37 gene expression in human intestinal T84 epithelial cells [24, 32] . In our study with primary chondrocytes, we found that TNFa induced IL37 protein expression, but we did not observe an increase on IL37 gene expression. An explanation for this could be that we missed the increase in IL37 gene expression induced by TNFa, because in our study we stimulated for 24 h with TNFa, whereas in the study with epithelial cells they stimulated for 12 h with TNFa.
A characteristic of OA pathobiology is elevated levels of pro-inflammatory cytokines [58] . This study shows that in chondrocytes, elevated levels of IL37 reduce IL1b, IL6 and IL8 expression both at the protein and at the mRNA level in the presence of IL1b. This confirms our hypothesis that elevated IL37 levels can play a role in blocking of pro-inflammatory cytokines during inflammation. The antiinflammatory potential of IL37 that we found is supported by previous studies with RAW macrophages, human monocytes and epithelial cells. In these studies, the elevated IL37 levels were combined with LPS or IL1b stimulation and found an almost complete suppression of the production of pro-inflammatory cytokines in the presence of IL37 [24] . In addition, neutralizing IL37 levels with siRNA-IL37 in PMBCs stimulated with LPS resulted in an increase in IL1, IL6 and TNFa production, indicating that endogenously produced IL37 plays a role in controlling the expression of pro-inflammatory cytokines [24] . Apart from OA, also in RA the disease activity correlates with elevated levels of pro-inflammatory cytokines. IL37 markedly suppressed the production of pro-inflammatory cytokines in PBMCs from RA patients. In addition, injection of an adenovirus overexpressing IL37 in the murine collageninduced arthritis model has been shown to reduce clinical and histological scores [27] . This indicates that also in inflammatory rheumatic diseases, IL37 reduces pro-inflammatory cytokine production and limits excessive inflammation.
The destructive potential of the pro-inflammatory cytokines IL1, IL6 and IL8 on articular cartilage has been shown in multiple studies. On articular cartilage, the proinflammatory cytokine IL1b is able to increase MMP release and collagen and proteoglycan degradation [12, 3639] . Additionally, inhibition of IL1b signalling by IL1Ra gene therapy in experimental OA animal models significantly reduced the severity of macroscopic lesions and could therefore reduce the progression of OA [40, 41] . The pro-inflammatory cytokine IL6 mediates OA cartilage destruction in mice via induction of hypoxia-inducible factor-2a, resulting in increased levels of the cartilagedegrading enzymes MMP3 and MMP13 [22] . Additionally, in bovine cartilage, blocking IL6 signalling via pretreatment with anti-IL6 Fab reduced sulphated glycosaminoglycan loss in an inflammatory environment [42] . Furthermore, increased release of the pro-inflammatory cytokine IL8 in OA synovial fluid recruits neutrophils to the cartilage surface and activates them. These cells are able to degrade type II collagen crosslinks and proteoglycans via the release of neutrophil elastase, encoded by the ELANE gene [4345] . Furthermore, IL8 is able to induce chondrocyte hypertrophy and calcification, through activation of the p38 mitogen-activated protein kinase signalling and chondrocyte transglutaminases, thereby promoting cartilage destruction [23] .
Taken together, reducing the pro-inflammatory cytokine expression is clearly an important target to slow down the process of cartilage degradation in OA. The above-mentioned treatments and inhibitors are specific for targeting one pro-inflammatory cytokine, whereas IL37 is able to reduce the production of IL1b as well as IL6 and IL8. This indicates that treatment of OA patients with IL37 could have a far more protective effect against cartilage degradation than the current blockers, by dampening the inflammatory status of the chondrocytes during the process of OA.
Another way to mediate cartilage degradation is via the induction of extracellular matrix-degrading enzymes, such as MMPs and ADAMTSs. In the present study, we found that elevated concentrations of IL37 reduce the IL1b-driven MMP1, MMP3 and MMP13 expression. In collagenase-induced experimental OA and spontaneously occurring OA, MMP3-deficient mice showed significantly decreased cartilage damage compared with control mice [46] . Furthermore, mice overexpressing MMP13 showed wild-type mice [49] . Double knockout of ADAMTS4 and ADAMTS5 protected mice against cartilage degradation and decreased OA severity, but these protective effects were comparable to the single ADAMTS5 knockout mice, indicating that ADAMTS5 is the major aggrecanase, at least in mice [50] . Overall, suppression of the MMP and ADAMTS production is a promising tool for inhibiting cartilage damage. Our study shows that elevated levels of IL37 attenuate not only the induction of pro-inflammatory cytokines but also the production of catabolic enzymes in human chondrocytes. In this way, IL37 targets the entire catabolic status of the chondrocytes. This supports IL37 as a potential and more effective therapeutic target in OA compared with the currently existing therapies.
In conclusion, we show that exposure of chondrocytes to an inflammatory stimulus results in a strong induction of IL37 expression. Furthermore, elevated levels of IL37 clearly reduce the IL1b-driven production of pro-inflammatory cytokines and catabolic enzymes. Pro-inflammatory cytokines and catabolic enzymes negatively affect cartilage integrity and accelerate the progression of OA. Therefore, elevating IL37 levels might be an interesting new therapeutic approach in OA that can contribute to the prevention of progressive cartilage degradation in OA patients by counter-regulating the catabolic status of human OA chondrocytes.
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